Clinical trials
Malignant Neoplasm of Breast clinical trials
Below are recruiting malignant neoplasm of breast clinical trials, each written for real people, not researchers. We’re tracking 181 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07331532Recruiting
New pet scan to detect annexin a2 in lung tumors
This trial tests a new injection called 68Ga-PFA2 for PET/CT scans to find a protein called Annexin A2 in lung cancer tumors. It aims to see if this scan can better detect or characterize these tumors in patients who will have a biopsy or surgery soon.
Beijing, Beijing MunicipalityAges 18–80 - NCT05430399RecruitingPhase 3
Utidelone vs docetaxel for HER2-negative breast cancer
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
Guangzhou, GangdongAges 18 years+ - NCT06966453RecruitingPhase 1/Phase 2
Study of disitamab vedotin for HER2-positive advanced breast cancer
This study tests a new drug called disitamab vedotin for people with advanced breast cancer that has a certain amount of HER2 protein. Depending on your HER2 and hormone receptor status, you may be eligible for one of three groups, each with different prior treatment requirements.
Daphne, AlabamaAges 18 years+ - NCT05835570Recruiting
PET scan using an integrin marker to find cancer
This trial uses a special PET/CT scan that targets a protein on some cancer cells to help detect and evaluate malignant tumors. It may help doctors better map tumors before any cancer treatment starts.
Wuhan, HubeiAges 18–85 - NCT06337214Recruiting
TCM therapy for energy in breast cancer patients
This trial tests whether adding Traditional Chinese Medicine (TCM) therapy can help maintain or improve your energy and vitality while you are undergoing standard cancer treatments like chemotherapy, radiation, or targeted therapy.
TaipeiAges 18–85 - NCT05417516RecruitingPhase 3
Partial breast radiation after lumpectomy in early breast cancer
This trial compares a shorter course of radiation focused on part of the breast versus a standard approach after lumpectomy. It aims to see if treating a smaller area can control the cancer while reducing treatment burden.
Darlinghurst, New South WalesAges 50–120 - NCT07702708Recruiting
AI predicts chemotherapy response in HR+/HER2- breast cancer
This trial uses AI to analyze your pre-treatment MRI and predict how well your tumor will respond to chemotherapy before surgery. It is for people with HR+/HER2- breast cancer who need chemo before their operation.
Fuzhou, FujianAges 18 years+ - NCT07500428Recruiting
Breast ultrasound AI study using existing images
This study uses existing breast ultrasound images to test how well artificial intelligence (AI) can interpret them. It may help improve future breast cancer detection tools.
BeijingAges 18–75 - NCT06686394RecruitingPhase 1/Phase 2
New drug combo for HER2+ breast cancer that has spread
This trial tests a new drug, patritumab deruxtecan, combined with other cancer treatments for people with advanced HER2+ breast cancer that cannot be removed by surgery. It may be an option if you have already tried other HER2-targeted therapies.
Aurora, ColoradoAges 18 years+ - NCT06380816RecruitingPhase 1/Phase 2
Study of UCB4594 for advanced cancers with HLA-G marker
This trial tests an experimental drug called UCB4594 for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if the drug is safe and effective against tumors that have a specific marker called HLA-G.
LondonAges 18 years+ - NCT05786716RecruitingPhase 2/Phase 3
Trastuzumab plus pertuzumab for HER2-mutated cancers
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
BelfastAges 12 years+ - NCT06304168Recruiting
Blood, tissue, and urine tests to detect cancer early
This study is testing whether simple blood, tissue, and urine samples can help find cancer earlier and identify where it started. Participating could help improve future cancer detection for everyone.
Rochester, MinnesotaAges 18 years+ - NCT06562777Recruiting
How symptoms differ between men and women during immunotherapy
This study looks at how symptoms during immunotherapy (a cancer treatment that boosts your immune system) may differ between men and women. Researchers will follow people with cancer who are starting immunotherapy to see if men and women report different side effects.
Portland, OregonAges 18 years+ - NCT06513962RecruitingPhase 3
Triptorelin to protect ovaries in young women with cancer
This study tests whether a medicine called triptorelin can protect the ovaries in young women and teens receiving strong chemotherapy for cancer. If you are newly diagnosed with a cancer (other than breast cancer) and are about to get certain chemotherapy drugs, this trial may help preserve your fertility.
Birmingham, AlabamaAges Up to 39 years - NCT06121089Recruiting
Surgery for early-stage cecal cancer
This trial is testing different surgical approaches for people with cecal cancer that hasn't spread. The goal is to find the best treatment option for patients whose tumors are at a stage where surgery can be curative.
MoscowAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT06877416Recruiting
Optimizing sequential ADC therapy for HER2-low breast cancer
This trial is for people with HER2-low breast cancer who have already received two or more antibody-drug conjugates (ADCs) in a row. Researchers want to find the best order to use these targeted therapies to get the most benefit.
Guangzhou, GuangdongAges Any age - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Sarasota, FloridaAges 12 years+ - NCT05603078Recruiting
Breast cancer surgery with a tumor-bed boost and standard radiation
This study looks at whether adding extra targeted radiation to the tumor area before breast-conserving surgery, then using modern breast surgery techniques and whole-breast radiation afterward, improves outcomes for early-stage breast cancer. You may be offered a treatment plan designed to better treat the area where the tumor was removed.
Beijing, Beijing MunicipalityAges Up to 55 years - NCT07339176RecruitingPhase 1/Phase 2
A trial of N17350 injected into tumors for advanced solid cancers
This trial tests an experimental drug, N17350, that is injected directly into tumors. It is for people with advanced solid tumors that have stopped responding to standard treatments or who cannot receive them. The study aims to see if this approach is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Duarte, CaliforniaAges 18 years+ - NCT07287098RecruitingPhase 2
Imlunestrant for premenopausal women with ER+/HER2- early breast cancer
This trial tests a new hormone-blocking pill (imlunestrant) in premenopausal women with early-stage ER+/HER2- breast cancer. Depending on whether you've had prior hormone therapy, the study will see if this treatment works better than standard options.
Birmingham, AlabamaAges 18 years+ - NCT06234137Recruiting
Chemo plus targeted therapy for advanced HER2+ breast cancer
This trial tests a combination of chemotherapy (docetaxel and carboplatin) plus two targeted drugs (Inetetamab and Pyrotinib) for people with locally advanced HER2-positive breast cancer that has not spread to other parts of the body. The goal is to see if this powerful combo can shrink the tumor before surgery or other treatments.
Wenzhou, ZhejiangAges 18–75 - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+
Hear when a new Malignant Neoplasm of Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignant neoplasm of breast?
- Yes. Clin2 currently lists 181 recruiting malignant neoplasm of breast studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignant neoplasm of breast trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignant neoplasm of breast trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.